Phase II trial of continuous drug infusions in advanced ovarian carcinoma: acivicin versus vinblastine

Sixty-six women with advanced ovarian carcinoma of coelomic epithelial origin were randomly assigned to one of two intravenous single-agent infusion treatment regimens, either acivicin (60 mg/m2/course, administered as a 72-hr infusion) or vinblastine (7.5 mg/m2/course, administered as a 120-hr infu...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1989-07, Vol.7 (2-3), p.255-260
Main Authors: EARHART, R. H, KHANDEKAR, J. D, FARAGGI, D, SCHINELLA, R. A, DAVIS, T. E
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adult
Aged
Aged, 80 and over
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - adverse effects
Antibiotics, Antineoplastic - therapeutic use
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Drug Evaluation
Female
Humans
Infusions, Intravenous
Isoxazoles - administration & dosage
Isoxazoles - adverse effects
Isoxazoles - therapeutic use
Medical sciences
Middle Aged
Ovarian Neoplasms - drug therapy
Oxazoles - therapeutic use
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sixty-six women with advanced ovarian carcinoma of coelomic epithelial origin were randomly assigned to one of two intravenous single-agent infusion treatment regimens, either acivicin (60 mg/m2/course, administered as a 72-hr infusion) or vinblastine (7.5 mg/m2/course, administered as a 120-hr infusion) every three weeks. All had progressive disease after one to three prior chemotherapeutic regimens. Of 62 patients who were evaluable for response, survival and toxicity, there was one partial response (2%) produced by vinblastine. Median survival was 13 weeks on either treatment arm. Three patients (10%) on the acivicin arm experienced life-threatening myelosuppression. Severe toxicities resulting from this treatment included myelosuppression (26%), neurotoxicity (16%), mucositis (3%) and vomiting (6%). Vinblastine was associated with one lethal pneumonia and five cases of life-threatening myelosuppression (16%); severe toxicities included myelosuppression (58%), genitourinary toxicity (6%), infection (3%), and edema (3%). Neither regimen produces useful clinical results in patients who have relapsed after prior chemotherapy for ovarian carcinoma.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00170870